Shi‐Ming Tu
Professor
University of Arkansas for Medical Sciences
faculty
Internal Medicine, College of Medicine
Research Areas
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Shi-Ming Tu's research focuses on cancer, particularly the stem cell theory of cancer and its implications for tumor heterogeneity and plasticity. His work also investigates specific cancer types, including advanced metastatic germ cell tumors and prostate cancer, exploring diagnostic and management strategies. He has examined the occurrence and implications of very late recurrences in germ cell tumors, as well as somatic-type malignancies in testicular germ cell tumors.
Tu is a highly cited researcher with an h-index of 36 and over 5,000 citations across 134 publications. His collaborations include work with Sunny Singh and Andrew Johns, among others at the University of Arkansas for Medical Sciences and the University of Central Arkansas. He leads a research group and has been recently active in research, with publications extending to 2022.
Metrics
- h-index: 36
- Publications: 134
- Citations: 5,043
Selected Publications
- Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers (2025) DOI
- Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases (2024) DOI
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024) DOI
- Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy (2023) DOI
- Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality (2022) DOI
- Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies (2022) DOI
Grants & Funding
- S2200, A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2). SouthWest Oncology Group Principal Investigator
- 297214 A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) BicycleTx Limited Principal Investigator
- 297214 A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) BicycleTx Limited - Pass Through: Medpace Clinical Research Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics